JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Extended sleeve lobectomy: one more step toward avoiding pneumonectomy in centrally located lung cancer.

BACKGROUND: The purpose of this study was to evaluate surgical outcomes of extended sleeve lobectomy (ESL) in centrally located non-small-cell lung cancer (NSCLC), sparing lung tissue and aggressively avoiding pneumonectomy.

METHODS: Patients who underwent ESL between January 2006 and January 2013 were included prospectively. An atypical bronchial anastomosis was used for sleeve lobectomy involving additional lobes or segments.

RESULTS: We included 27 patients, aged 62.7 ± 8.2 years (range, 49-83 years), with a forced expiratory volume in 1 second (FEV1) of 2.27 ± 0.6 (range, 1.6-2.7). According to the Okada classification, 16 cases were type A (right upper lobe + middle lobe ± segment 6), 7 cases were type B (left upper lobe + segment 6), and 2 cases were type C (left lower lobe + segments 4-5); we additionally classified 2 patients with right lower lobe tumors involving the right main bronchus as type D (right lower lobe + middle lobe). Anastomosis was performed between the right superior and right main bronchial stumps. Eleven patients underwent combined pulmonary angioplasties. Complete resection was achieved in all cases. There were no operative deaths. Mean segment reimplantation was 4.5 ± 0.84 (range, 3-6), resulting in a mean FEV1 improvement of 0.620 ± 0.16 (right-sided ESL) and 0.393 ± 0.21 (left-sided ESL). The complication rate was 25% (no immediate anastomosis-related complications; 1 case of delayed bronchial stenosis). No local recurrence was reported. At 6 months, mean FEV1 was 1.5 ± 0.4 (right-sided ESL) and 1.4 ± 0.3 (left-sided ESL). Mean follow-up time was 28 ± 19 months (range, 7-72 months). Overall 5-year survival was 62%.

CONCLUSIONS: In patients with centrally located NSCLC, lung-sparing ESL, whose safety and reliability rival that of pneumonectomy, should be considered. Functional effectiveness is higher with right-sided than with left-sided ESL.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app